VICTORIA, British Columbia - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in biotherapeutic research powered by artificial intelligence, has announced a significant leap in life sciences research and development with the creation of a Foundation AI Model.
This model, which integrates Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology, is set to enhance the accuracy of biological data analysis and expedite drug discovery.
The HYFT technology identifies unique 'fingerprints' within biological sequences, which act as anchor points connecting various data layers. BioStrand's platform boasts a knowledge graph mapping 25 billion relationships across 660 million data objects, linking sequence, structural, and functional data to scientific literature. This comprehensive mapping facilitates a holistic understanding of genes, proteins, and biological pathways.
The combination of HYFTs with stacked LLMs allows the AI model to decode the complex language of proteins, which is essential for the development of antibody drugs and precision medicine.
LLMs, initially developed for Natural Language Processing (NLP), can now be applied to protein sequences, enhancing tasks such as protein structure prediction and antibody binding optimization.
The advanced AI model utilizes LLM stacking to combine different LLMs linked to specific features identified by HYFTs. For example, this enables differentiation between binding and non-binding antibodies, even when they share similar HYFT patterns. This methodology promises to not only speed up the development of targeted treatments but also to reduce research and development costs.
Dr. Dirk Van Hyfte, Co-Founder and Head of Innovation at BioStrand, emphasized the model's role in pushing the boundaries of biotech research and establishing a new standard for the application of AI in biological challenges.
ImmunoPrecise's CEO, Dr. Jennifer Bath, will discuss the company's AI-driven solutions at the H.C. Wainwright 1st Annual Artificial Intelligence Based Drug Discovery (NASDAQ:WBD) & Development Virtual Conference today. Additionally, Dr. Van Hyfte will present the findings at the HIMSS24 conference in Orlando, Florida, next week.
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology group that employs systems biology, multi-omics modeling, and complex AI systems in its proprietary technologies for antibody discovery. The company's subsidiaries span North America and Europe, providing highly specialized services for therapeutic biologics discovery, development, and out-licensing.
This news is based on a press release statement and contains forward-looking information subject to risks and uncertainties. The company cautions that actual results may vary due to factors such as the integration of LENSai platform with HYFT technology not yielding expected results and other risks outlined in its regulatory filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.